03/10/2023
Amphastar receives FDA nod for naloxone hydrochloride
Naloxone hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.
Amphastar has received the Food and Drug Administration’s blessing for naloxone hydrochloride nasal spray in a dosage strength of 4 mg.
Naloxone hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.
[Read more: Amphastar obtains FDA nod for generic Vasostrict]
Naloxone hydrochloride nasal spray had a market value of $250 million for the 12 months ended Dec. 31, 2022, according to IQVIA.
[Read more: FDA gives Amphastar tentative OK for vasopressin injection]